Insulin degludec
- Generic Name
- Insulin degludec
- Brand Names
- Ryzodeg, Tresiba, Xultophy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 844439-96-9
- Unique Ingredient Identifier
- 54Q18076QB
- Background
Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. ...
- Indication
Insulin degludec is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.
- Associated Conditions
- Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Associated Therapies
- -
A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily
- Conditions
- Interventions
- First Posted Date
- 2013-03-19
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 40
- Registration Number
- NCT01814137
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Istanbul, Turkey
A Trial Investigating the Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart 15 in Subjects With Type 1 Diabetes
- First Posted Date
- 2013-01-23
- Last Posted Date
- 2015-03-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 33
- Registration Number
- NCT01773798
A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin
- Conditions
- Interventions
- First Posted Date
- 2012-10-24
- Last Posted Date
- 2018-04-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 274
- Registration Number
- NCT01713530
- Locations
- 🇳🇴
Novo Nordisk Investigational Site, Stavanger, Norway
A Trial Comparing the Effect of Exercise on Blood Glucose in Subjects With Type 1 Diabetes, Who Are Treated With Either Insulin Degludec or Insulin Glargine
- Conditions
- Interventions
- First Posted Date
- 2012-10-11
- Last Posted Date
- 2016-12-16
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 40
- Registration Number
- NCT01704417
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
- Conditions
- Interventions
- First Posted Date
- 2012-08-14
- Last Posted Date
- 2017-09-25
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 346
- Registration Number
- NCT01664247
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Stevenage, United Kingdom
A Trial Investigating the Absolute Bioavailability of Insulin Degludec in Healthy Subjects
- First Posted Date
- 2012-06-20
- Last Posted Date
- 2015-02-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 18
- Registration Number
- NCT01623375
A Trial Investigating the Pharmacodynamic Properties of NN5401 in Subjects With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2012-05-03
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 22
- Registration Number
- NCT01590836
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin
- Conditions
- Interventions
- First Posted Date
- 2012-04-04
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 145
- Registration Number
- NCT01570751
- Locations
- 🇵🇷
Novo Nordisk Investigational Site, Manati, Puerto Rico
A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2012-04-03
- Last Posted Date
- 2016-02-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT01569841
- Locations
- 🇺🇸
Novo Nordisk Clinical Trial Call Center, Minneapolis, Minnesota, United States
A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2012-01-20
- Last Posted Date
- 2019-06-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 350
- Registration Number
- NCT01513473
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Sheffield, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.